CY2226B1 - Pyrimidine derivatives as hmg-coa reductase inhibitors - Google Patents

Pyrimidine derivatives as hmg-coa reductase inhibitors

Info

Publication number
CY2226B1
CY2226B1 CY0100015A CY0100015A CY2226B1 CY 2226 B1 CY2226 B1 CY 2226B1 CY 0100015 A CY0100015 A CY 0100015A CY 0100015 A CY0100015 A CY 0100015A CY 2226 B1 CY2226 B1 CY 2226B1
Authority
CY
Cyprus
Prior art keywords
hmg
coa reductase
reductase inhibitors
pyrimidine derivatives
hyperlipoproteinemia
Prior art date
Application number
CY0100015A
Other languages
English (en)
Inventor
Haruo Koike
Masamichi Watanabe
Kentaro Hirai
Teruyuki Ishiba
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16216169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2226(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of CY2226B1 publication Critical patent/CY2226B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY0100015A 1991-07-01 2001-06-27 Pyrimidine derivatives as hmg-coa reductase inhibitors CY2226B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18801591 1991-07-01

Publications (1)

Publication Number Publication Date
CY2226B1 true CY2226B1 (en) 2003-04-18

Family

ID=16216169

Family Applications (2)

Application Number Title Priority Date Filing Date
CY0100015A CY2226B1 (en) 1991-07-01 2001-06-27 Pyrimidine derivatives as hmg-coa reductase inhibitors
CY2004008C CY2004008I2 (el) 1991-07-01 2015-06-15 ΠΑΡΑΓΩΓΑ ΠΥΡΙΜΙΔΙΝΗΣ ΣΑΝ ΑΝΑΣΤΟΛΕΙΣ HMG-CoA ΑΝΑΓΩΓΑΣΗΣ

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2004008C CY2004008I2 (el) 1991-07-01 2015-06-15 ΠΑΡΑΓΩΓΑ ΠΥΡΙΜΙΔΙΝΗΣ ΣΑΝ ΑΝΑΣΤΟΛΕΙΣ HMG-CoA ΑΝΑΓΩΓΑΣΗΣ

Country Status (18)

Country Link
US (2) US5260440A (Direct)
EP (1) EP0521471B1 (Direct)
JP (1) JP2648897B2 (Direct)
KR (1) KR960005951B1 (Direct)
AT (1) ATE197149T1 (Direct)
CA (1) CA2072945C (Direct)
CL (1) CL2010000113A1 (Direct)
CY (2) CY2226B1 (Direct)
DE (2) DE69231530T2 (Direct)
DK (1) DK0521471T3 (Direct)
ES (1) ES2153824T3 (Direct)
GE (1) GEP20022693B (Direct)
GR (1) GR3035189T3 (Direct)
HU (2) HU220624B1 (Direct)
LU (1) LU91042I2 (Direct)
NL (1) NL300125I2 (Direct)
PT (1) PT521471E (Direct)
TW (1) TW203044B (Direct)

Families Citing this family (394)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677455A (en) 1994-09-06 1997-10-14 Ube Industries, Ltd. Preparation of 3-oxy-5-oxo-6-heptenoic acid derivatives
US5958934A (en) * 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
US5952331A (en) * 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
CZ298235B6 (cs) * 1999-03-10 2007-08-01 Lonza Ag Zpusob výroby N-[5-(difenylfosfinoylmethyl)-4-(4-fluorfenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethansulfonamidu
US6160115A (en) * 1999-03-10 2000-12-12 Lonza Ag Process for preparing N-[5-(diphenylphosphinoylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin -2-yl]-N-methylmethanesulfonamide
ES2251392T3 (es) 1999-07-13 2006-05-01 Lonza Ag Procedimiento para preparar 2-amino-4-(4-fluorofenil)-6-alquilpirimidina-5-carboxilatos.
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001247745B2 (en) 2000-03-24 2006-08-31 Pharmacia Corporation Amidino compounds useful as nitric oxide synthase inhibitors
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
US6956131B2 (en) 2000-04-13 2005-10-18 Pharmacia Corporation 2-amino-3, 4 heptenoic compounds useful as nitric oxide synthase inhibitors
US6787668B2 (en) 2000-04-13 2004-09-07 Pharmacia Corporation 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AR030416A1 (es) 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
US6545170B2 (en) 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
GB0011163D0 (en) * 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
CA2455170A1 (en) * 2000-07-31 2002-02-07 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
WO2002010139A1 (en) 2000-08-01 2002-02-07 Pharmacia Corporation Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
AR030741A1 (es) 2000-09-15 2003-09-03 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
IL155173A0 (en) * 2000-10-12 2003-10-31 Nissan Chemical Ind Ltd Prophylactic and therapeutic agent for diabetic complications
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
CN1329520C (zh) 2001-02-02 2007-08-01 三菱化学株式会社 制备(3r,5s)－(e)－7－[2－环丙基－4－(4－氟苯基)－喹啉－3－基]－3,5－二羟基庚－6－烯酸酯的方法
ES2258141T3 (es) 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
CN1301977C (zh) 2001-07-13 2007-02-28 阿斯特拉曾尼卡英国有限公司 氨基嘧啶化合物的制备方法
YU31004A (sh) * 2001-10-18 2006-08-17 Bristol-Myers Squibb Company Mimetici humanog glukagonu sličnog peptida-1 i njihova upotreba u lečenju dijabetesa i srodnih stanja
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
SE0103509D0 (sv) * 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
US6984645B2 (en) * 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
US7672397B2 (en) * 2002-05-14 2010-03-02 Otmar Irscheid Method for producing a transmission signal
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
EP1585736A2 (en) * 2002-05-21 2005-10-19 Ranbaxy Laboratories, Ltd. Process for the preparation of rosuvastatin
US20050182106A1 (en) * 2002-07-11 2005-08-18 Sankyo Company, Limited Medicinal composition for mitigating blood lipid or lowering blood homocysteine
US20050182036A1 (en) * 2002-08-02 2005-08-18 Sankyo Company, Limited Medicinal composition containing an HMG-CoA reductase inhibitor
US20050187204A1 (en) * 2002-08-08 2005-08-25 Sankyo Company, Limited Medicinal composition for lowering blood lipid level
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US7414119B2 (en) 2002-09-20 2008-08-19 Verenium Corporation Aldolases, nucleic acids encoding them and methods for making and using them
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
ES2344057T3 (es) * 2002-10-23 2010-08-17 Bristol-Myers Squibb Company Inhibidores de la dipeptidil peptidasa iv basados en nitrilos de glicina.
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
DE60239428D1 (Direct) 2002-12-10 2011-04-21 Ranbaxy Lab Ltd
EP1578731B1 (en) 2002-12-16 2009-11-11 AstraZeneca UK Limited Process for the preparation of pyrimidine compounds
GB0229243D0 (en) * 2002-12-16 2003-01-22 Avecia Ltd Compounds and process
DE60323536D1 (de) 2002-12-20 2008-10-23 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US20040176425A1 (en) * 2003-01-24 2004-09-09 Washburn William N. Cycloalkyl containing anilide ligands for the thyroid receptor
KR20080008440A (ko) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
MXPA05009976A (es) * 2003-03-17 2005-11-04 Japan Tobacco Inc Metodo para incrementar la biodisponibilidad oral del 2-metilpropantioato de s-[2-([[1- 2-etilbutil) ciclohexil] carbonil] amino) fenilo].
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
SG182849A1 (en) * 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2004096234A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
AU2004233693B2 (en) * 2003-04-28 2007-07-19 Funahashi, Toru Adiponectin production enhancer
WO2004096276A1 (ja) * 2003-04-28 2004-11-11 Sankyo Company, Limited 糖取り込み能増強剤
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7166638B2 (en) * 2003-05-27 2007-01-23 Nicox S.A. Statin derivatives
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
CA2529820A1 (en) * 2003-06-18 2004-12-29 Teva Pharmaceutical Industries Ltd Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
WO2005007110A2 (en) * 2003-07-11 2005-01-27 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
WO2005021511A1 (en) * 2003-08-27 2005-03-10 Hetero Drugs Limited A novel process for amorphous rosuvastatin calcium
EP1562912A2 (en) * 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US20050171207A1 (en) * 2003-09-26 2005-08-04 Myriad Genetics, Incorporated Method and composition for combination treatment of neurodegenerative disorders
CN1886383A (zh) * 2003-10-22 2006-12-27 兰贝克赛实验室有限公司 无定形罗苏伐他汀钙的制备方法
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
DE602004020649D1 (de) * 2003-11-07 2009-05-28 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
DK1689757T3 (en) * 2003-11-12 2014-12-08 Sino Med Internat Alliance Inc HETEROCYCLIC DRY ACID COMPOUNDS
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
CA2546894C (en) * 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
EP1699760B1 (en) 2003-12-23 2017-05-17 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
KR20060135712A (ko) * 2003-12-24 2006-12-29 테바 파마슈티컬 인더스트리즈 리미티드 높은 ｓｙｎ형 대 ａｎｔｉ형 비율을 지닌 스타틴의 제조방법
WO2005063294A1 (ja) 2003-12-30 2005-07-14 Kowa Company, Ltd. γ-セクレターゼ複合体形成阻害剤
US20070161700A1 (en) * 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
CZ200486A3 (cs) * 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
EP1737828A1 (en) * 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Amorphous magnesium salts of rosuvastatin
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
US20070078109A1 (en) * 2004-02-13 2007-04-05 David Platt Compositions and methods used to treat acne and candida
WO2005079847A1 (ja) 2004-02-25 2005-09-01 Kowa Company, Ltd. Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法
US8309574B2 (en) * 2004-02-25 2012-11-13 Kowa Company, Ltd. Nuclear transfer promoter for Rac protein and method of screening the same
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
US7161004B2 (en) * 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US7145040B2 (en) * 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
JP2008505975A (ja) * 2004-07-12 2008-02-28 フェノミックス コーポレーション 制約されたシアノ化合物
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
CZ298330B6 (cs) * 2004-07-19 2007-08-29 Zentiva, A. S. Zpusob výroby 4-(4-fluorfenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)-5-pyrimidinkarbaldehydu a jeho použití
DK1778251T3 (da) 2004-07-27 2011-07-18 Gilead Sciences Inc Nukleosidphosphatkonjugater som anti-HIV-midler
EP1773128A2 (en) * 2004-08-02 2007-04-18 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
CN100412065C (zh) * 2004-08-13 2008-08-20 天津天士力集团有限公司 一种4-（对氟苯基）-6-异丙基-2-甲胺基嘧啶-5-甲酸甲酯的合成方法
US20070244107A1 (en) * 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
EP1797046A2 (en) * 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
CN1763015B (zh) * 2004-10-22 2011-06-22 四川抗菌素工业研究所有限公司 一种罗舒伐他汀及其药用盐的制备方法及中间体
AU2005297984B2 (en) 2004-10-27 2009-11-12 Daiichi Sankyo Company, Limited Benzene compound having 2 or more substituents
AU2005315608B2 (en) * 2004-12-15 2011-03-31 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
US7872012B2 (en) * 2004-12-23 2011-01-18 Zhejiang Hisun Pharma Co., Ltd. Pyrimidinone compounds and preparation and use thereof
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
US7635699B2 (en) * 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) * 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006076598A2 (en) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) * 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076569A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
CN100351240C (zh) * 2005-01-19 2007-11-28 安徽省庆云医药化工有限公司 瑞舒伐他汀钙的合成方法
US7932387B2 (en) * 2005-01-31 2011-04-26 Basf Se Crystalline forms of rosuvastatin calcium salt
EP1849765A4 (en) * 2005-02-02 2010-05-05 Ajinomoto Kk PROCESS FOR PREPARING A PYRIMIDINE COMPOUND
ATE421518T1 (de) * 2005-02-10 2009-02-15 Bristol Myers Squibb Co Dihydrochinazolinone als 5ht-modulatoren
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
TWI353981B (en) 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US20070293535A1 (en) * 2005-02-24 2007-12-20 Kowa Company, Ltd. Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame
WO2006100689A1 (en) * 2005-03-22 2006-09-28 Unichem Laboratories Limited Process for preparation of rosuvastatin
WO2006106526A1 (en) * 2005-04-04 2006-10-12 Unichem Laboratories Limited Process for preparation of calcium salt of rosuvastatin
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
CN1307187C (zh) * 2005-05-16 2007-03-28 浙江海正药业股份有限公司 瑞舒伐他汀及其中间体的制备方法
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US20060275356A1 (en) * 2005-05-25 2006-12-07 Burgess James W Pharmaceutical compositions for treating or preventing coronary artery disease
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
AR053495A1 (es) * 2005-05-26 2007-05-09 Bristol Myers Squibb Co Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas
WO2006128954A1 (en) * 2005-06-01 2006-12-07 Fermion Oy Process for the preparation of n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide
US20060287342A1 (en) * 2005-06-17 2006-12-21 Mikkilineni Amarendra B Triazolopyrimidine heterocycles as cannabinoid receptor modulators
US7317012B2 (en) * 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7629342B2 (en) * 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
TW200726765A (en) * 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
CN102807530B (zh) * 2005-06-24 2015-08-05 力奇制药公司 制备不含杂质的无定型罗苏伐他汀钙的方法
CN101203496B (zh) * 2005-06-24 2011-04-20 力奇制药公司 纯的无定形瑞舒伐他汀钙的制备方法
CZ299215B6 (cs) * 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
WO2007016353A2 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
US7868169B2 (en) * 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
CA2619867A1 (en) * 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Rosuvastatin calcium with a low salt by-product content
CN100436428C (zh) * 2005-08-22 2008-11-26 鲁南制药集团股份有限公司 瑞舒伐他汀及其盐的制备方法
CN100352821C (zh) * 2005-08-22 2007-12-05 鲁南制药集团股份有限公司 一种瑞舒伐他汀钙中间体的制备方法
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
EP1919393A2 (en) * 2005-09-01 2008-05-14 Prescient Medical, Inc. Drugs coated on a device to treat vulnerable plaque
WO2007035395A2 (en) * 2005-09-16 2007-03-29 Virginia Commonwealth University Intellectual Property Foundation Therapeutic compositions comprising chorionic gonadotropins and hmg coa reductase inhibitors
JP2008526897A (ja) * 2005-10-03 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチンのジアステレオマー精製
MX2007006647A (es) * 2005-10-04 2007-07-25 Teva Pharma Preparacion de rosuvastatina.
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
EP2487154B1 (en) 2005-10-31 2013-10-16 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
CN1958593B (zh) * 2005-11-03 2010-05-05 上海医药工业研究院 一种用于合成瑞舒伐他汀钙的中间体的制备方法
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EA015682B1 (ru) * 2005-12-20 2011-10-31 Лек Фармасьютиклз Д.Д. Фармацевтическая композиция
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20070238669A1 (en) * 2006-01-11 2007-10-11 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions
AU2007208965B2 (en) * 2006-01-30 2011-12-08 Cadila Healthcare Limited A process for manufacturing Rosuvastatin Potassium and crystalline and amorphous forms thereof
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
EA019971B1 (ru) 2006-03-07 2014-07-30 Верениум Корпорейшн Альдолазы, кодирующие их нуклеиновые кислоты и способы их получения и применения
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
AU2007243282A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
EP2024341B1 (en) * 2006-05-03 2015-12-02 MSN Laboratories Private Limited Novel process for statins and its pharmaceutically acceptable salts thereof
US20100022457A1 (en) * 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
JPWO2008001499A1 (ja) 2006-06-29 2009-11-26 興和株式会社 関節リウマチの予防及び／又は治療薬
US20080044326A1 (en) * 2006-07-04 2008-02-21 Esencia Co., Ltd. Sterilizer for baby products
CA2656366A1 (en) 2006-07-05 2008-01-10 Nycomed Gmbh Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
WO2008015563A2 (en) * 2006-08-04 2008-02-07 Glenmark Pharmaceuticals Limited Salts of rosuvastatin and processes for their preparation
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
WO2008044243A2 (en) 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
US8318933B2 (en) * 2006-10-31 2012-11-27 Aurobindo Pharma Ltd Process for preparing rosuvastatin calcium
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
EP2086946A2 (en) * 2006-11-29 2009-08-12 Dr. Reddy's Laboratories Ltd. Rosuvastatin dehydroabietylamine salt
US8212034B2 (en) * 2006-12-13 2012-07-03 Aurobindo Pharma Ltd. Process for preparing rosuvastatin calcium
WO2008093205A2 (en) * 2007-01-31 2008-08-07 Orchid Chemicals & Pharmaceuticals Limited A method for the purification of rosuvastatin intermediate
CA2677809A1 (en) * 2007-02-08 2008-08-14 Aurobindo Pharma Limited An improved process for preparation of rosuvastatin calcium
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
CN101795684A (zh) * 2007-04-09 2010-08-04 赛多斯有限责任公司 他汀类化合物与抗肥胖药的组合
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
EP2142551B1 (en) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
JP2009531466A (ja) * 2007-04-18 2009-09-03 テバ ファーマシューティカル インダストリーズ リミティド ＨＭＧ−ＣｏＡ還元酵素阻害剤の中間体の製造方法
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
KR101530393B1 (ko) 2007-04-27 2015-06-19 고쿠리쓰다이가쿠호진 규슈다이가쿠 폐질환 치료약
US20080287529A1 (en) * 2007-05-18 2008-11-20 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
IN2009KN04568A (Direct) 2007-06-01 2015-08-28 Univ Princeton
EP2546232A1 (en) 2007-06-20 2013-01-16 Merck Sharp & Dohme Corp. Diphenyl Substituted Alkanes
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
EP2178846A1 (en) * 2007-07-12 2010-04-28 Teva Pharmaceutical Industries Ltd. Rosuvastatin intermediates and their preparation
CN101808995A (zh) * 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
EP2022784A1 (en) * 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009027081A2 (en) * 2007-08-28 2009-03-05 Ratiopharm Gmbh Process for preparing pentanoic diacid derivatives
CN101376647B (zh) * 2007-08-31 2010-12-08 中山奕安泰医药科技有限公司 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法
US20090082380A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched rosuvastatin
HU230981B1 (hu) * 2007-10-12 2019-08-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin só előállítására
HU230637B1 (hu) * 2007-10-12 2017-05-29 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin intermedierek előállítására
CN101910171A (zh) 2007-11-01 2010-12-08 百时美施贵宝公司 可用作糖皮质激素受体AP-1和/或者NF-κB活性调节剂的非甾类化合物及其用途
ES2718047T3 (es) 2008-01-11 2019-06-27 Reata Pharmaceuticals Inc Triterpenoides sintéticos y métodos de uso en el tratamiento de la enfermedad
TR200800269A2 (tr) * 2008-01-15 2009-08-21 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Stabil farmasötik formülasyon ve hazırlama yöntemleri
CN101591301B (zh) * 2008-05-27 2011-01-12 常州制药厂有限公司 一种3,5-二羟基庚-6-烯酸衍生物的制备方法
EP2298745B1 (en) * 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
CN101591302B (zh) * 2008-05-27 2011-08-31 常州制药厂有限公司 一种庚烯酸酯衍生物的制备方法
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
EP2309992B1 (en) 2008-06-27 2017-10-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ阻害剤化合物の塩
EP2161024A1 (de) 2008-09-05 2010-03-10 Universitätsklinikum Hamburg-Eppendorf Kombinationspräparat zur Behandlung von Krebs
EP2350025A1 (en) * 2008-09-30 2011-08-03 Aurobindo Pharma Limited An improved process for preparing pyrimidine propenaldehyde
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2373609B1 (en) 2008-12-19 2013-10-16 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
PL2387566T3 (pl) 2009-01-14 2014-10-31 Krka Tovarna Zdravil D D Novo Mesto Sposób przygotowania rosuwastatyny
CA2749727A1 (en) 2009-01-15 2010-07-22 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Process for the preparation of rosuvastatin salts
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
EP2264015A1 (en) 2009-02-02 2010-12-22 LEK Pharmaceuticals d.d. Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
KR101160152B1 (ko) * 2009-02-24 2012-06-27 한미사이언스 주식회사 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
GB0904100D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of rosuvastatin lactols as medicaments
GB0904104D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Atorvastatin and rosuvastatin derivatives
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
CN102448456A (zh) 2009-03-27 2012-05-09 百时美施贵宝公司 用dpp-iv抑制剂预防重度有害心血管事件的方法
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
US8470805B2 (en) 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
HUP0900285A2 (en) 2009-05-07 2011-01-28 Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag Rosuvastatin salts and preparation thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
KR101157314B1 (ko) 2009-06-05 2012-06-15 주식회사종근당 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법
WO2011019326A2 (en) 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
WO2011018185A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
WO2011021058A1 (en) 2009-08-17 2011-02-24 Aurobindo Pharma Limited Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester
SMT201800495T1 (it) 2009-11-13 2018-11-09 Astrazeneca Ab Formulazioni di compresse a doppio strato
ES2693686T3 (es) 2009-11-13 2018-12-13 Astrazeneca Ab Formulaciones de comprimidos de liberación inmediata
JP5798123B2 (ja) 2009-11-13 2015-10-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 低質量のメトホルミン製剤
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
US20130115622A1 (en) 2009-12-14 2013-05-09 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
EP2336116A1 (en) 2009-12-16 2011-06-22 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
WO2011074016A1 (en) 2009-12-17 2011-06-23 Matrix Laboratories Ltd Novel polymorphic forms of rosuvastatin calcium and process for preparation of the same
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
CN102212082B (zh) * 2010-04-05 2015-03-04 重庆博腾制药科技股份有限公司 瑞舒伐他汀钙中间体及制备方法
CN102219749B (zh) * 2010-04-14 2013-07-17 上海京新生物医药有限公司 一种制备瑞苏伐他汀钙的方法
WO2011130459A1 (en) 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2560970A1 (en) 2010-04-23 2013-02-27 Ranbaxy Laboratories Limited NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS
EP2566465A2 (en) 2010-05-04 2013-03-13 Mahmut Bilgic Stable rosuvastatin formulations
WO2011141934A1 (en) 2010-05-13 2011-11-17 Matrix Laboratories Ltd. An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
WO2011152803A1 (en) 2010-06-03 2011-12-08 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin
TR201005326A2 (tr) 2010-06-30 2012-01-23 B�Lg�� Mahmut Çoklu dozaj formları.
KR101292238B1 (ko) 2010-07-01 2013-07-31 주식회사유한양행 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 그의 중간체의 제조방법
EP2423195A1 (en) 2010-07-26 2012-02-29 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
CN101955463B (zh) * 2010-08-04 2012-01-04 重庆博腾制药科技股份有限公司 瑞舒伐他汀钙中间体的制备方法
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US20130210860A1 (en) 2010-10-06 2013-08-15 Kowa Co., Ltd. Prophylactic and/or therapeutic agent against lymphedema
MX2010011006A (es) * 2010-10-06 2012-04-18 Senosiain S A De C V Lab Nueva sal de un derivado de pirimidina.
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
WO2012063115A2 (en) 2010-11-11 2012-05-18 Jubilant Life Sciences Ltd. Process for the preparation of rosuvastatin calcium via novel amine intermediate
TR201009399A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Hızlı çözünen efervesan rosuvastatin formülasyonları.
HU230737B1 (hu) 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
HU230987B1 (hu) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
HU229260B1 (en) 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
CN102584717B (zh) * 2011-01-17 2014-12-10 浙江九洲药业股份有限公司 用于制备罗苏伐他汀的中间体及相关制备方法和用途
US9126975B2 (en) 2011-01-18 2015-09-08 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of statins in the presence of base
WO2012097744A1 (en) 2011-01-20 2012-07-26 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
KR20140006013A (ko) 2011-01-28 2014-01-15 사노피 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체
US9487506B2 (en) 2011-04-13 2016-11-08 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
DE202012011888U1 (de) * 2011-04-18 2013-03-21 Basf Se Kristallines Mehrkomponentensystem von Rosuvastatin-Calciumsalz und Vanillin
US20140294959A1 (en) 2011-05-20 2014-10-02 Astrazeneca Uk Limited Pharmaceutical Composition of Rosuvastatin Calcium
WO2012172564A1 (en) * 2011-05-25 2012-12-20 Dr. Reddy's Laboratories Limited Process for preparation of rosuvastatin calcium
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
WO2013046222A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited A process for the preparation of amorphous rosuvastatin calcium
EA028278B1 (ru) 2011-09-16 2017-10-31 Ридженерон Фармасьютикалз, Инк. СПОСОБЫ СНИЖЕНИЯ УРОВНЕЙ ЛИПОПРОТЕИНА(а) ПОСРЕДСТВОМ ВВЕДЕНИЯ ИНГИБИТОРА ПРОПРОТЕИНКОНВЕРТАЗЫ СУБТИЛИЗИН/КЕКСИН-9 (PCSK9)
EP2765859B1 (en) 2011-10-13 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
EP2785851A2 (en) 2011-11-28 2014-10-08 Mylan Laboratories, Limited Process for producing chiral statin side chain intermediates employing candida antarctica lipase b
EP2602249B1 (en) 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
KR20140108705A (ko) 2011-12-29 2014-09-12 트러스티즈 오브 터프츠 칼리지 재생 및 염증 반응을 제어하기 위한 생체물질의 기능화
EP2809319B1 (en) 2012-02-02 2018-04-18 The University of Sydney Improvements in tear film stability
DK2844233T3 (da) 2012-05-01 2020-07-13 Althera Life Sciences Llc Oral tabletformulering bestående af en fastsat kombination af rosuvastatin og ezetimib til behandling af hyperlipidæmi og kardiovaskulære sygdomme
HK1205141A1 (en) 2012-06-15 2015-12-11 霍夫曼-拉罗奇有限公司 Anti-pcsk9 antibodies, formulations, dosing, and methods of use
US8729092B2 (en) 2012-09-24 2014-05-20 Terence J. Scallen Rosuvastatin enantiomer compounds
CN103709107B (zh) * 2012-09-29 2016-04-20 安徽省庆云医药化工有限公司 瑞舒伐他汀甲酯的新晶型及其制备方法
CN103044339A (zh) * 2012-10-15 2013-04-17 武汉市江润精细化工有限责任公司 瑞舒伐他汀钙中间体的制备方法
RU2015123738A (ru) 2012-11-20 2017-01-10 Лексикон Фармасьютикалз, Инк. Ингибиторы котранспортера натрий-глюкозы 1
WO2014108795A2 (en) 2013-01-10 2014-07-17 Aurobindo Pharma Limited An improved process for the preparation of chiral diol sulfones and statins
ITVI20130039A1 (it) 2013-02-20 2014-08-21 F I S Fabbrica Italiana Sint I S P A Processo per la preparazione di intermedi chiave per la sintesi di statine
US20160045497A1 (en) 2013-03-12 2016-02-18 Lg Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
SG11201507305SA (en) 2013-03-14 2015-10-29 Boryung Pharm Pharmaceutical combination drug
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
WO2014203045A1 (en) 2013-06-20 2014-12-24 Lupin Limited A novel, green and cost effective process for synthesis of tert-butyl (3r,5s)-6-oxo-3,5-dihydroxy-3,5-o-isopropylidene-hexanoate
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
WO2015008294A1 (en) 2013-07-16 2015-01-22 Suven Life Sciences Limited Process for the preparation of rosuvastatin calcium and preparation of its novel intermediates
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN106062003A (zh) 2013-11-12 2016-10-26 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
JP6536871B2 (ja) 2013-12-02 2019-07-03 国立大学法人京都大学 Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法
CN103724278B (zh) * 2013-12-12 2019-03-29 江苏阿尔法药业有限公司 他汀类中间体及其衍生物的制备方法
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
JP6596339B2 (ja) * 2014-02-06 2019-10-23 株式会社エーピーアイ コーポレーション ロスバスタチンカルシウム及びその中間体の製造方法
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
JP6240346B2 (ja) * 2014-03-07 2017-11-29 ▲凱▼菜英医▲薬▼集▲団▼（天津）股▲フン▼有限公司 ロスバスタチンカルシウムを製造するための中間体化合物、及びそれを用いてロスバスタチンカルシウムを製造する方法
CN103896979B (zh) * 2014-03-31 2015-03-18 南京欧信医药技术有限公司 一种化合物的合成方法
CN103951552B (zh) * 2014-04-11 2015-09-30 浙江宏元药业有限公司 瑞舒伐他汀中间体及其制备方法
CN104151252B (zh) * 2014-05-07 2016-09-28 兰州大学 一种制备[6-异丙基-4-(4-氟苯基)-2-硫基-5-基]甲酸酯的方法
EP3148587B1 (en) 2014-05-30 2021-02-24 Pfizer Inc Carbonitrile derivatives as selective androgen receptor modulators
PL3169353T3 (pl) 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2016056658A1 (ja) * 2014-10-10 2016-04-14 株式会社エーピーアイ コーポレーション スタチン系化合物の精製方法
CN104356155B (zh) * 2014-10-20 2017-01-18 浙江新东港药业股份有限公司 一种(s)‑叔丁基二甲基硅氧基‑戊二酸单酰胺的制备方法
CN104529909B (zh) * 2014-12-26 2016-08-24 江西富祥药业股份有限公司 一种瑞舒伐他汀钙中间体的结晶方法
CN104592130A (zh) * 2014-12-30 2015-05-06 江苏阿尔法药业有限公司 一种瑞舒伐他汀主链的新的制备方法
CN104628653B (zh) * 2015-01-28 2018-04-03 湖北益泰药业有限公司 合成瑞舒伐他汀钙关键中间体的方法
KR20160126700A (ko) 2015-04-24 2016-11-02 미래파인켐 주식회사 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법
CN104829600B (zh) * 2015-05-05 2017-11-07 浙江新东港药业股份有限公司 一种合成瑞舒伐他汀的中间体的合成工艺
KR20240172758A (ko) 2015-08-18 2024-12-10 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
CN108472249A (zh) 2015-10-23 2018-08-31 林德拉有限公司 用于治疗剂缓释的胃驻留系统及其使用方法
CN105367502A (zh) * 2015-12-07 2016-03-02 浙江宏元药业有限公司 瑞舒伐他汀钙中间体及制备瑞舒伐他汀钙中间体和瑞舒伐他汀钙的方法
AU2016366192B2 (en) 2015-12-08 2022-08-04 Nortiva Bio, Inc. Geometric configurations for gastric residence systems
EP3445751B9 (en) 2016-04-18 2023-07-26 Morepen Laboratories Limited New polymorphic form of crystalline rosuvastatin calcium&novel processes for crystalline as well as amorphous rosuvastatin calcium
JP7189772B2 (ja) 2016-05-27 2022-12-14 リンドラ セラピューティクス， インコーポレイティド 胃内滞留システムのための材料構造物
CN118766834A (zh) 2016-09-30 2024-10-15 林德拉治疗公司 用于金刚烷类药物缓释的胃驻留系统
EP3572075A2 (en) 2017-01-23 2019-11-27 Dong Wha Pharm. Co., Ltd. Complex formulation comprising hmg-coa reductase inhibitor and clopidogrel
AU2018279853B2 (en) 2017-06-09 2024-07-04 Nortiva Bio, Inc. Gastric residence systems with release rate-modulating films
CN107698518A (zh) * 2017-06-20 2018-02-16 迪沙药业集团（天津）药物研究有限公司 一种瑞舒伐他汀钙差向异构体杂质的制备方法
ES2969496T3 (es) 2017-08-01 2024-05-20 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
EP3791874B1 (en) 2018-05-08 2025-12-24 National University Corporation Okayama University Pemafibrate and pitavastatin for use in reducing hypertension as a major risk factor for cardiovascular diseases
WO2020017575A1 (ja) 2018-07-19 2020-01-23 国立大学法人京都大学 多能性幹細胞由来の板状軟骨およびその製造方法
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
JP2022502393A (ja) 2018-09-26 2022-01-11 レクシコン ファーマシューティカルズ インコーポレイテッド Ｎ−（１−（（２−（ジメチルアミノ）エチル）アミノ）−２−メチル−１−オキソプロパン−２−イル）−４−（４−（２−メチル−５−（（２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）−３，４，５−トリヒドロキシ−６−（メチルチオ）テトラヒドロ−２ｈ−ピラン−２−イル）ベンジル）フェニル）ブタンアミドの結晶形態及びそれらの合成方法
JP7224001B2 (ja) 2018-12-21 2023-02-17 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
PH12021551686A1 (en) 2019-01-18 2022-05-16 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN109796414B (zh) * 2019-02-26 2022-05-20 中国药科大学 一种采用微通道模块化反应装置连续制备瑞舒伐他汀中间体的方法
SG11202109928WA (en) 2019-03-13 2021-10-28 National Univ Corporation Hamamatsu Univ School Of Medicine Pharmaceutical composition for treating aortic aneurysm
KR102740370B1 (ko) * 2019-03-28 2024-12-06 에스케이하이닉스 주식회사 메모리 시스템, 메모리 컨트롤러 및 그 동작 방법
PH12021553276A1 (en) 2019-07-31 2022-09-12 Intas Pharmaceuticals Ltd Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate
BR112022001783A2 (pt) 2019-07-31 2022-03-22 Tecnimede Sociedade Tecnico Medicinal Sa Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos.
EP4063512A4 (en) 2019-11-22 2024-01-03 API Corporation CARBONYL REDUCTASE, NUCLEIC ACID ENCODING SAME, AND METHOD FOR PRODUCING AN OPTICALLY ACTIVE COMPOUND USING SAME
EP4076459A4 (en) 2019-12-17 2023-12-20 Merck Sharp & Dohme LLC Prmt5 inhibitors
US20230108452A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP4108260A4 (en) 2020-02-21 2024-03-06 JSR Corporation COMPOSITION FOR RELIEVING PULMONARY HYPERTENSION, METHOD FOR PREDICTING PULMONARY HYPERTENSION
TW202302090A (zh) * 2021-04-30 2023-01-16 大陸商江蘇恒瑞醫藥股份有限公司 血小板生成素受體激動劑的給藥方案
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders
WO2025168652A1 (en) 2024-02-05 2025-08-14 Astrazeneca Ab Azd-0780 in combination with a statin for use in lowering ldl-c levels and treating cardiovacular diseases
TW202539678A (zh) 2024-03-20 2025-10-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
WO2025196155A1 (en) 2024-03-20 2025-09-25 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2025196153A1 (en) 2024-03-20 2025-09-25 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2025238159A1 (en) 2024-05-16 2025-11-20 Astrazeneca Ab Combination therapy comprising azd0780 and ezetimibe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87929B (pt) 1987-07-10 1995-03-01 Hoechst Ag Processo para a preparacao de derivados de acido 3-desmetil-mevalonico e de composicoes farmaceuticas que os contem
EP0308736A3 (en) 1987-09-12 1990-02-14 Nissan Chemical Industries Ltd. Pyrimidine type mevalonolactones
US4868185A (en) 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
AU3214689A (en) * 1988-10-06 1990-05-01 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
USRE37314E1 (en) 2001-08-07
DK0521471T3 (da) 2001-02-05
DE69231530T2 (de) 2001-06-13
JP2648897B2 (ja) 1997-09-03
CA2072945A1 (en) 1993-01-02
DE122009000017I1 (de) 2009-11-05
HK1011986A1 (en) 1999-07-23
EP0521471B1 (en) 2000-10-25
CA2072945C (en) 2001-07-31
NL300125I2 (nl) 2003-08-01
KR930002325A (ko) 1993-02-23
GEP20022693B (en) 2002-05-10
GR3035189T3 (en) 2001-04-30
ES2153824T3 (es) 2001-03-16
KR960005951B1 (ko) 1996-05-06
HU0004863D0 (Direct) 2001-02-28
ATE197149T1 (de) 2000-11-15
NL300125I1 (nl) 2003-07-01
CY2004008I1 (el) 2010-07-28
DE69231530D1 (de) 2000-11-30
JPH05178841A (ja) 1993-07-20
HUT61531A (en) 1993-01-28
CL2010000113A1 (es) 2010-07-02
CY2004008I2 (el) 2016-10-05
TW203044B (Direct) 1993-04-01
HU219407B (hu) 2001-04-28
DE122009000017I2 (de) 2010-10-21
PT521471E (pt) 2001-04-30
HU9202179D0 (en) 1992-10-28
EP0521471A1 (en) 1993-01-07
HU220624B1 (hu) 2002-03-28
LU91042I2 (fr) 2003-11-24
US5260440A (en) 1993-11-09

Similar Documents

Publication Publication Date Title
CY2226B1 (en) Pyrimidine derivatives as hmg-coa reductase inhibitors
MXPA02012252A (es) Inhibidores de la reductasa 3-hidroxi-3-metilglutaril-coenzima a (hmg-coa) y metodo.
PT1686119E (pt) Derivados de pirimidin-4-ona como inibidores de ldl-pla2
AU2058992A (en) HMG-COA reductase inhibitors
EP0433842A3 (en) 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
EP0352864A3 (en) Compounds active as inhibitors of the cholesterol biosynthesis
MY121399A (en) Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
AU3103800A (en) Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
IL134272A0 (en) Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia
AU3006992A (en) Stabilized Pharmeceutical Compositions of HMG-CoA Reductase Inhibitors
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
AU6527090A (en) Substituted cyclohexene derivatives as hmg-coa reductase inhibitors
AU4751800A (en) Pyrimidinones derivatives for the treatment of atherosclerosis
GR3020689T3 (en) Pyrrole derivatives
AU7761398A (en) Hmg-coa reductase inhibitor preparation process
GR880100332A (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΡΕΔΟΥΚΤΑΣΗΣ HMG-CοA ΠΟΥ ΠΕΡΙΕΧΕΙ ΦΩΣΦΟΡΟ,ΝΕΑ ΕΝΔΙΑΜΕΣΑ ΚΑΙ ΜΕΘΟΔΟΣ
AU4543699A (en) Multibinding inhibitors of hmg-coa reductase
BG105003A (en) Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer
AU645287B2 (en) Quinoline and pyridine anchors for HMG-CoA reductase inhibitors
IT1255470B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
AU2177701A (en) Use of hmg-coa reductase inhibitors for treating seborrhea
AU4457897A (en) Nad or nadp containing pharmaceutical compositions for treating aids
AU2002300546A1 (en) Combinations of HMG-CoA Reductase Inhibitors and Nicotinic Acid and Methods for Treating Hyperlipidemia
NZ501368A (en) 3Beta-27-dihydroxy-5-cholesten-7-one and its use in pharmaceutical compositions
IE892191L (en) 3-KETO HMG-CoA REDUCTASE INHIBITORS